Drugs, Carugi (Gaef): "Plasma derivatives strategic sector, out of payback"

The appeal, 'develop the supply chain by increasing plasma collection and refining industrial processes'

"The plasma derivatives sector is strategic for our country, it represents a production value of approximately 300 million euros. In Italy there are 5 companies with more than 1,500 employees. It has a huge social and ethical value because we collect plasma from Italian donors and transform it into a finished product. To promote the development of the plasma derivatives supply chain, we need to increase plasma collection and refine industrial processes. We are very committed to improving yields by guaranteeing greater quantities of products compared to the quantity of plasma collected". Francesco Carugi, president of the Farmindustria blood derivatives group (Gaef), said this today in Milan, participating in the event promoted by the biopharmaceutical company Kedrion Biopharma 'Science meets humanity. The future of biopharmaceuticals between plasma and new therapies'.

"Plasma derivatives should be excluded from the payback system", adds Carugi who also asks the institutions for "greater planning. We need - he explains - to know well in advance the quantities of plasma needed to fill the part that the national self-sufficiency system cannot cover".